Department of Otorhinolaryngology, Inje University College of Medicine, Ilsan Paik Hospital, 2240 Daehwa-dong, IlsanSeo-gu, Goyang-si, Gyeonggi-do, Republic of Korea.
J Plast Reconstr Aesthet Surg. 2013 Aug;66(8):1058-63. doi: 10.1016/j.bjps.2013.04.012. Epub 2013 May 15.
An attempt has been made to produce a new 'balance' in facial dynamics between a paralysed and a non-paralysed face with reduction of synkinesis, by concomitant injection of botulinum toxin A (BTX-A) on both sides in patients with long-lasting facial sequelae.
Prospective clinical study.
University hospital.
Forty-two consecutive patients who recovered partially from facial nerve paralysis were enrolled for this study. The amount injected per site of the paralysed side with synkinesis varied from 1.5 to 2.5 U, and the total dose used per patient was 10-26 U (mean 17.12±5.3 U). That of the non-paralysed side with muscular hypertrophy varied from 2.5 to 5 U, and the total dose used per patient was 35-72 U (mean 52.6±9.7 U). All patients had been evaluated by the Sunnybrook (SB) facial nerve grading systems and developed dynamic facial asymmetry ratio.
After administration of injection of BTX-A on both sides of the face, relief of facial synkinesis and enhancement of facial symmetry were observed in all patients. Before the injection, the patients showed an SB score of 38.8±10.68. After the injection, changes of synkinesis and symmetry score were 7.9±1.81 and 8.4±3.25, respectively, resulting in a 58.4±12.46 score at the last evaluation. Before the administration, the mean±standard deviation (SD) value of dynamic facial asymmetry was 0.83±0.06 and it was increased significantly to 0.90±0.05 1 month after administration.
After BTX-A injection on both sides for synkinesis and contralateral hypertrophy, the patients showed significant suppression of the synkinesis and improvement of facial symmetry with resulting elevated quality of life, social interaction, personal appearance and food intake.
通过在两侧同时注射肉毒毒素 A(BTX-A)来减少面肌联带运动,试图在患有长期面部后遗症的患者中为瘫痪侧和非瘫痪侧的面部动力学创造新的“平衡”。
前瞻性临床研究。
大学医院。
42 例部分面神经麻痹恢复的连续患者纳入本研究。患侧面肌联带运动的每个注射部位的注射量为 1.5 至 2.5U,每位患者的总剂量为 10-26U(平均 17.12±5.3U)。患侧肌肉肥大的每个注射部位的注射量为 2.5 至 5U,每位患者的总剂量为 35-72U(平均 52.6±9.7U)。所有患者均采用桑尼布鲁克(SB)面神经分级系统进行评估,并建立了动态面部不对称比。
在面部两侧注射 BTX-A 后,所有患者的面部联带运动均得到缓解,面部对称性得到增强。注射前,患者的 SB 评分为 38.8±10.68。注射后,联带运动和对称性评分分别为 7.9±1.81 和 8.4±3.25,最后评估时得分为 58.4±12.46。给药前,动态面部不对称的平均±标准差(SD)值为 0.83±0.06,给药后 1 个月显著增加至 0.90±0.05。
在两侧同时注射 BTX-A 治疗联带运动和对侧肥大后,患者的联带运动明显受到抑制,面部对称性得到改善,从而提高了生活质量、社交互动、个人形象和食物摄入。